Davis Robert M 4

What Happened

• Robert M. Davis, Merck’s Chairman, CEO & President and a director, was granted derivative awards on 2026-05-05 totaling 187,421 units (47,724 and 139,697). Each line is reported at $0.00 because these are compensation awards (derivative instruments), not open-market purchases or sales.
• The filing identifies restricted stock units (RSUs) and an option-style award. The RSUs convert to common shares and both awards vest over time rather than deliver immediate stock or cash.

Key Details

• Transaction date: 2026-05-05; Report filed: 2026-05-07 (timely filing).
• Reported prices: $0.00 (awards/grants — no cash paid by insider).
• Total units granted: 47,724 and 139,697 (187,421 combined).
• Shares owned after transaction: not disclosed in the provided filing summary.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to receive one share.
  • F2: The RSUs vest and will be distributed in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
  • F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
• Transaction code: A = Grant/Award/Other acquisition.

Context

• These are compensation awards (RSUs and an option) that vest over the next three years; they do not indicate an immediate buy or sell by the insider. Such grants are common executive compensation and are different from open-market purchases (which some investors view as a stronger bullish signal).